Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
Chem Biodivers ; 19(5): e202200102, 2022 May.
Article de Anglais | MEDLINE | ID: mdl-35362194

RÉSUMÉ

Prostate cancer is the second most common malignancy in men and the development of effective therapeutic strategies remains challenging when more advanced, androgen-independent or insensitive forms are involved. Accordingly, we have evaluated, using flow cytometry, confocal microscopy and image analysis, the anti-proliferative effects of (+)-2,3,9-trimethoxypterocarpan [(+)-PTC, 1] on relevant human prostate cancer cells as well as its capacity to control mitosis within them. In particular, the studies reported herein reveal that (+)-PTC exerts anti-proliferative activity against the PC-3 cell lines by regulating cell-cycle progression with mitosis being arrested in the prophase or prometaphase. Furthermore, it emerges that treatment of the target cells with this compound results in the formation of monopolar spindles, disorganized centrosomes and extensively disrupted γ-tubulin distributions while centriole replication remains unaffected. Such effects suggest (+)-PTC should be considered as a possible therapy for androgen-insensitive/independent prostate cancer.


Sujet(s)
Microtubules , Tumeurs de la prostate , Androgènes , Lignée cellulaire , Humains , Mâle , Mitose , Tumeurs de la prostate/traitement médicamenteux , Tumeurs de la prostate/métabolisme , Appareil du fuseau/métabolisme , Tubuline/métabolisme
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...